Form 4: Forte Biosciences CEO Wagner Reports RSU Vesting & Tax Withholding

Forte Biosciences' CEO, Paul A. Wagner, reported the vesting of 1,250 restricted stock units and the subsequent disposition of 164 shares for tax withholding.

Summary

• Paul A. Wagner, CEO, Secretary, and Chair of the Board of Forte Biosciences, Inc. (FBRX), reported transactions on January 1, 2026.
• 1,250 Restricted Stock Units (RSUs) vested, converting into 1,250 shares of common stock.
• Following the vesting, 164 shares of common stock were disposed of to cover tax liabilities at a price of $27.27 per share.
• After these transactions, Wagner directly beneficially owns 83,178 shares of common stock and 5,000 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing is a routine insider transaction related to executive compensation. It reflects a scheduled vesting event and tax withholding, which are neutral operational activities. It doesn't indicate any new positive or negative operational or financial performance, but confirms ongoing executive compensation structure.

Positives

• Vesting of RSUs indicates continued service and compensation for the CEO, aligning executive interests with long-term company performance.
• The transaction is a standard compensation event, not a discretionary sale of shares, reflecting a pre-established equity incentive plan.

Negatives

• Disposition of 164 shares for tax withholding reduces the CEO's direct shareholding, although this is a routine and expected part of RSU vesting.

Future Outlook

The filing details a standard RSU vesting schedule, indicating ongoing compensation for the reporting person, with future vesting events expected quarterly as per the 2021 Equity Incentive Plan.

Management Comments

• Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
• On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld.
• Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions related to executive compensation, specifically RSU vesting and tax-related share withholding. Such transactions are common across all industries, particularly in biotechnology where executive compensation often includes equity incentives tied to long-term performance and retention.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice in the biotechnology and broader corporate sectors, aligning executive incentives with shareholder value over time.
• The disposition of shares to cover tax obligations upon RSU vesting is a typical and expected event, reflecting standard tax treatment of equity compensation.
• The vesting schedule of 1/16th quarterly, subject to continued service, is a common structure designed for executive retention and long-term commitment, comparable to practices at companies like Amgen or Gilead Sciences for their senior executives.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting is a standard part of equity compensation plans, but the overall impact from this specific transaction is negligible. The CEO's continued equity ownership aligns interests.
• Employees: The filing highlights the company's executive compensation structure, which may be relevant for employee understanding of equity incentives.

Next Steps

• Continued vesting of the remaining 5,000 Restricted Stock Units on a quarterly basis, subject to Paul A. Wagner's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and subsequent tax withholding. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It merely confirms the execution of a pre-existing compensation plan for a key executive, which is a neutral event for the stock's fundamental value.

Keywords

Forte Biosciences, FBRX, Paul A. Wagner, SEC Form 4, Restricted Stock Units, RSU Vesting, Insider Transaction, Stock Compensation, Tax Withholding